Dr. Haver's estrogen safety claims need more context

What did @drmaryclaire actually say?

Dr. Mary Claire Haver and OB-GYN Dr. Corinne Menn argued that "there are very few true absolutes" for estrogen contraindications, and that a family history of breast cancer is "not a contraindication to hormone therapy." They listed legitimate reasons to pause or avoid estrogen, including active blood clots, severe liver disease, recent significant cardiac events, unexplained postmenopausal bleeding, and a personal active estrogen-dependent breast cancer diagnosis. Their core point: clinicians and patients are over-applying restrictions that the evidence doesn't actually support.

This is a real and documented problem in menopause medicine. Multiple surveys of clinicians show that fear of breast cancer, often based on misread family history or misapplied Women's Health Initiative data, drives unnecessary refusals to prescribe hormone therapy. The creators are speaking to something genuinely under-discussed.

Does the science back this up?

Mostly, yes. The framing around contraindications aligns with current guidance from major menopause societies, though some nuance is missing. The North American Menopause Society (NAMS) 2022 position statement does not list family history of breast cancer as an absolute contraindication to menopausal hormone therapy. Neither does ACOG. The real list of firm contraindications is short.

On the breast cancer point specifically: Vinogradova et al. (2019, BMJ) found that combined estrogen-progestogen therapy was associated with increased breast cancer risk, but that the risk varied substantially by formulation, duration, and individual baseline. Importantly, family history alone, in the absence of a personal diagnosis or high-risk genetic mutation, does not put someone in the category of "cannot take estrogen." Manson et al. (2017, JAMA) reanalyzed WHI data and showed that for women 50-59, or within 10 years of menopause onset, estrogen-only therapy was actually associated with reduced breast cancer incidence. The science does not support a blanket ban based on a relative's diagnosis.

What did they get wrong (or right)?

They got the headline right. The overcorrection in clinical practice around family history is real, well-documented, and harmful to patients who could benefit from hormone therapy. Credit where it's due.

However, the claim that "in medicine, there are no absolutes" is rhetorically useful but clinically imprecise. There are genuine hard stops. An active estrogen-receptor-positive breast cancer currently being treated is, by any reasonable clinical standard, an absolute contraindication. Most oncology guidelines, including those from ASCO, are explicit about this. Even here, the creators do name personal active breast cancer as one of their "big ones," so they aren't actually contradicting themselves, they're just using imprecise framing to make a broader point.

The blood clot discussion also deserves a closer look. They mention a "recent thrombosis" as a reason to be careful, which is accurate, but oral estrogen carries a meaningfully different thrombotic risk profile than transdermal estrogen. Canonico et al. (2007, Circulation) showed that transdermal estradiol does not carry the elevated VTE risk associated with oral formulations. That distinction matters enormously for clinical decision-making and was not mentioned.

What should you actually know?

The practical takeaway is this: if you've been told you can't take estrogen because your mother had breast cancer, that guidance deserves a second opinion from a menopause-literate clinician. Current evidence does not support that restriction. Family history without a personal diagnosis or confirmed high-penetrance genetic mutation (like BRCA1/2) is not a standard contraindication.

At the same time, the mode of estrogen delivery matters in ways this video skips over. Route of administration, dose, whether progestogen is added and which type, and your individual cardiovascular and clotting history all factor into safety. The NAMS 2022 position statement recommends individualized risk assessment rather than population-level bans. A family history of blood clots is also not the same as having had a blood clot yourself, and those carry different clinical weight. This conversation is a good starting point, but it is not a substitute for a personalized assessment.